Background. Few studies have prospectively evaluated the impact of highly active antiretroviral therapy (HAART) on body weight and lean body mass (LBM) or explored the impact of baseline immunologic or virological changes on these parameters.
Methods. Adult AIDS Clinical Trials Group (ACTG) protocol 892 was a prospective, 48-week, multisite observational study of body composition conducted during 1997-2000 among 224 antiretroviral-naive and antiretroviral-experienced subjects coenrolled into various adult ACTG antiretroviral studies. Assessments included human immunodeficiency virus type 1 (HIV-1) RNA load (by polymerase chain reaction); T lymphocyte subset analysis; Karnofsky score; height (baseline only); weight, LBM, and fat (by bioelectrical impedance analysis); and functional performance (by questionnaire).
Results. Overall, only modest median increases in body weight (1.9 kg) and LBM (0.6 kg) occurred after 16 weeks of therapy. Significantly greater median increases in body weight (2.1 vs. 0.5 kg;
) occurred in P p .045 subjects who achieved virological suppression (HIV-1 RNA load, !500 copies/mL) at week 16 than in subjects who did not. Subjects who were antiretroviral naive at baseline gained more weight (median increase in body weight, 2.6 vs. 0.0 kg;
) and LBM (1.0 vs. 0.1 kg; ) after 16 weeks of treatment than did subjects P ! .001 P p .002 who were antiretroviral experienced. Subjects with lower baseline CD4 cell counts (!200 cells/mm 3 ) and subjects with higher baseline HIV-1 RNA loads (у100,000 copies/mL) were more likely to show increases in LBM of 11.5 kg ( and , respectively). P p .013 P p .005 Conclusions. HAART had modestly favorable effects on body composition, particularly in patients with greater pretreatment immunocompromise and virological compromise. The difference between antiretroviral-naive and antiretroviral-experienced subjects with regard to the ability to achieve increased body weight and LBM requires more study.
Decreases in body weight and lean body mass (LBM) are common problems in HIV-infected persons. Depletion of body cell mass may occur early in asymptomatic HIV-infected patients before progression to AIDS [1] , suggesting that such depletion may be related, at least in part, to underlying HIV infection, rather than to the opportunistic infections associated with AIDS. This relationship is further suggested by the finding of an association between HIV load and weight loss [2, 3] . Only a few studies have prospectively evaluated the impact of virus suppression induced by HAART on LBM or have explored the impact of baseline immunologic or virological parameters on increases in weight or LBM after the initiation of HAART [4] [5] [6] . AIDS Clinical Trials Group (ACTG) 892 was a 48-week multicenter observational study conducted during 1997-2000 to assess changes in weight, LBM, and functional performance during HAART in subjects coenrolled into adult ACTG antiretroviral studies. The primary objective of this study was to determine the short-term relationship between changes in plasma HIV-1 RNA levels following initiation of HAART and changes in LBM during therapy.
METHODS
Subjects evaluated for ACTG 892 were coenrolled from 6 adult ACTG antiretroviral studies, some of which targeted primarily antiretroviral-naive persons, whereas others targeted primarily antiretroviral-experienced persons (table 1) . Subjects participating in study protocols for antiretroviral-experienced persons continued to receive their former antiretroviral regimens up to the time they switched to study-mandated HAART. Each of these studies for antiretroviral-experienced persons excluded subjects with prior adefovir exposure. Inclusion criteria initially required HIV-1 RNA levels before entry to be у10,000 copies/mL, but this was later changed to у5000 copies/mL. Study subjects were recruited over a wide range of body mass indexes of !28. Subjects who had diarrhea, impaired oral intake due to mucositis, or diabetes or who were taking therapies designed to improve appetite or weight gain were excluded from the study. Institutional review board approval was obtained for the protocol by all participating adult ACTG sites, and written informed consent was obtained from each subject before enrollment.
Assessments for ACTG 892 were done at specified study weeks that coincided with the study visits for the coenrolled adult ACTG antiretroviral study. Measurements included HIV-1 RNA load (by Amplicor 1.0 PCR; Roche); T lymphocyte subset analysis; Karnofsky score; height (baseline only); weight, LBM, and fat (by bioelectrical impedance analysis [BIA]); and functional performance (by questionnaire).
Height and weight were measured and BIA was performed in accordance with adult ACTG procedures for metabolic studies. Subjects wore hospital gowns for measurements of weight, and electrode placement for BIA was standardized during supervised central training. All BIA was performed by use of RJL Systems bioelectrical impedance analyzers, which provided readings of resistance and reactance. Fat and LBM were calculated with use of published equations that had been validated in analyses of patients with HIV infection [13] . Karnofsky scores were determined at each visit. The Karnofsky score is a widely used measurement of health status in HIV medicine that provides a descriptive, ordinal scale by which health care professionals rate a patient's functional status at 10-point intervals from 0 to 100. Scoring is based on observable characteristics and patient interview and addresses physical performance, as well as symptoms and ability to work [14] .
Functional performance was measured by means of the selfadministered Human Activity Profile (HAP) questionnaire, which has been previously validated in healthy and impaired populations [15] [16] [17] [18] [19] . Each item in the questionnaire represents a common activity requiring a known amount of average energy expenditure (i.e., the metabolic equivalent [MET]), with 1 MET being the approximate amount of oxygen consumed by an average person at rest, sitting upright. The 94 items contained in the HAP cover a range of 1-10 METs. As specified in the HAP manual, 2 aggregate scores were derived from these responses [19] . The maximum activity score corresponds to the activity requiring the most oxygen that the subject still performed. The adjusted activity score corrects for the premorbid activity level of the subject.
Differences between groups with respect to continuous variables were assessed by Kruskal-Wallis tests. Within-group changes were assessed by Wilcoxon signed rank tests. Differences between groups with respect to categorical covariates were assessed by exact tests. Several hypothesis tests were performed, each at the .05 level of significance and without correction for multiple testing. Thus, results should be viewed with caution, with hypotheses tests interpreted as data trends rather than as absolute indicators of statistical significance. No imputation was done for variables used in the analyses, except for a lastobservation-carried-forward imputation for HIV-1 RNA load (data for !5% of subjects needed imputation). A comparison of antiretroviral-naive with antiretroviral-experienced subjects was added post hoc after noting the confounding potential of baseline treatment status.
RESULTS
ACTG 892 opened in November of 1997 and closed in March of 2000. As shown in table 1, body composition and functional performance were assessed for 143 subjects participating in 4 ACTG trials involving antiretroviral-experienced subjects and from 1 trial predominantly involving antiretroviral-naive subjects. In addition, weight, height, and BIA data from 81 subjects from A5005s-a metabolic substudy of an antiretroviral therapy trial (ACTG 384) involving antiretroviral-naive subjects-who met ACTG 892 entry criteria were included in the body composition analysis. A fairly even distribution of subjects with body mass indices of !23 or у23 was obtained. Of the 224 total subjects, 133 (59.4%) were antiretroviral naive, and 91 (40.6%) were antiretroviral experienced.
Baseline characteristics. Baseline demographic and clinical characteristics of subjects are shown in table 2. Sex, ethnicity, injection drug use history, and CD4 cell counts were comparable in the antiretroviral-naive and antiretroviral-experienced cohorts. The antiretroviral-naive group had a larger proportion of the youngest subjects (age, 18-29 years), higher HIV-1 RNA levels, and more subjects with the highest (100) Karnofsky scores, compared with the antiretroviral-experienced cohort.
Baseline body composition characteristics are shown in table 3. No differences based on antiretroviral status were noted. Differences in baseline body composition according to baseline CD4 cell counts were present. Subjects with baseline CD4 cell counts of !200 cells/mm 3 had a lower median LBM (56.6 vs.
kg;
) and demonstrated a trend toward a lower P p .028 body mass index (22.8 vs. 23.5; ) than did subjects P p .054 with baseline CD4 cell counts of у200 cells/mm 3 . Baseline body composition parameters did not differ according to baseline HIV-1 RNA levels (!100,000 vs. у100,000 copies/mL).
Changes in body composition after receipt of HAART for 16 and 48 weeks. After receipt of HAART for 16 and 48 weeks by the group as a whole, modest median increases in body weight (1.9 kg and 1.9 kg, respectively) and LBM (0.6 kg and 0.9 kg, respectively) were observed. At week 16, a significantly greater median increase in body weight was observed among subjects who had achieved virological suppression (HIV-1 RNA level, !500 copies/mL) at this time point than among those who had not ( ) (table 4) . At week 48, a P p .045 significantly greater median increase in LBM was observed among subjects who had an HIV-1 RNA level of !500 copies/ mL at this time point than among subjects who had an HIV-1 RNA load of у500 copies/mL ( ) (table 4) . P p .035 When changes in body composition were compared on the basis of antiretroviral status at baseline, significantly greater increases in body weight, LBM, and fat occurred at week 16 in subjects who were antiretroviral naive at baseline, compared with those who were antiretroviral experienced at baseline (table 5). This finding could not be explained as results driven by any 1 or 2 of the antiretroviral studies to which the subjects were coenrolled. Modest median increases in body weight at week 16 were seen in both studies involving antiretroviral-naive subjects, whereas median decreases or no changes in weight were seen in all 4 trials involving antiretroviral-experienced subjects. This antiretroviral status-based difference in body composition was sustained through week 48.
In assessing the relationship between virological response and body composition in this study, certain factors are worthy of note. The percentage of subjects who achieved virological suppression to !500 copies/mL differed by antiretroviral status. At 16 weeks, 93% of the antiretroviral-naive subjects with available data had achieved virological suppression, compared with 44% of antiretroviral-experienced subjects ( ). In the anti-P ! .001 retroviral-experienced cohort, 82% of the subjects had received adefovir as part of their antiretroviral regimens. Because adefovir has been associated with substantial weight loss [20, 21] , changes in body weight were compared in subjects who did and subjects who did not receive adefovir. Subjects who did not receive adefovir had significant gains in body weight, compared with subjects who received adefovir (median change, 1.45 vs. Ϫ0.30 kg;
). P p .021 Effect of baseline characteristics on body composition changes after receipt of HAART for 16 and 48 weeks. Low CD4 cell counts (table 6) and high HIV-1 RNA levels (table 7) at baseline were associated with greater increases in LBM (11.5 kg) at week 16, but this was no longer significant at week 48. Although a trend toward increased LBM in subjects with a lower body mass index at baseline was also noted, this was not significant (data not shown).
Functional performance assessments. Functional performance assessments at baseline, week 16, and week 48 were available for 142 subjects. At baseline, functional performance was similar in the antiretroviral-naive and antiretroviralexperienced cohorts. Compared with subjects with у200 CD4 cells/mm 3 !100,000 copies/mL, compared with subjects with HIV-1 RNA levels of у100,000 copies/mL at baseline. The relationship between changes in functional performance and increases in LBM was assessed at the week 16 and 48 time points in both antiretroviral cohorts. At week 16, no difference in changes in functional performance were found in either antiretroviral group when subjects with an increase of 11.5 kg in LBM were compared with subjects with no such increase. However, at week 48, median changes in adjusted activity score (2.0 vs. Ϫ3.5; ) and maximum activity score (1.0 vs. Ϫ1.5; P p .039 ) were higher among antiretroviral-naive subjects who P p .050 demonstrated an increased LBM of 11.5 kg, compared with those who did not. Similar analysis at week 48 in the antiretroviral-experienced cohort revealed no differences in changes in functional performance stratified according to LBM increases.
DISCUSSION
In this study, the initiation of HAART was associated with modest median body weight increases of 1.9 kg and 1.9 kg and modest median LBM increases of 0.6 kg and 0.9 kg after 16 weeks and 48 weeks, respectively. The modest nature of the increases in weight and LBM found in this study are consistent with those reported in the literature [6, 22, 23] . Published studies have shown either positive correlation [5, 6, 22] or no correlation [4, 23] between HAART-induced decreases in virus burden and increases in weight and LBM. In our study, a relationship was found between decreases in HIV-1 RNA loads and increases in weight at week 16 and between decreases in HIV-1 RNA loads and increases in LBM at week 48.
The hypothesis that virological and immunologic factors affect changes in weight and LBM is supported by the data obtained in this study. As expected, severe immunosuppression at baseline (as defined by CD4 cell counts of !200 cells/mm 3 ) was associated with decreased weight and LBM at baseline. Of greater interest, the magnitude of the increases in weight and LBM following HAART in this study corresponded to the degree of immunocompromise and virological compromise at in body composition at weeks 16 and 48, by baseline antiretroviral treatment (ART) status, in baseline. The greatest increases in weight and LBM occurred in patients with greater degrees of immunocompromise (as evidenced by CD4 cell counts of !200/mm 3 ) or in those with virological compromise, as evidenced by HIV RNA levels of у100,000 copies/mL.
The antiretroviral-experienced cohort in our study demonstrated poor increases in weight and LBM following HAART. The association between adefovir use and weight loss suggests that treatment with this drug may have been a factor in limiting increases in weight and LBM in this cohort. Whether adefovir was the sole factor in the demonstrated inability to increase weight and LBM is unclear. Other studies have reported that HAART is associated with incomplete weight and LBM recovery in certain subpopulations of HIV-infected subjects [23] [24] [25] . It is possible that being antiretroviral-experienced selects for other factors that limit the ability to regain weight and LBM. With the dramatic decrease in incidence of opportunistic infections associated with HAART, it appears to be highly unlikely that secondary infections or malabsorption would explain poor improvement in weight and LBM in the treatment-experienced subjects. Recent evidence suggests that a progressive decrease in LBM in the HAART era may be related to catabolic cytokines [26] . Differential cytokine production between the antiretroviral-naive and antiretroviral-experienced cohorts may have resulted in the differences seen in this study.
BIA has well-recognized limitations [27, 28] . Some studies have shown that dual-energy radiographic absorptiometry is superior to BIA for measurement of whole-body LBM in patients with HIV infection [28] . However, every effort was made to optimize the results obtained with this method, including standardized measurements of height and weight, which are major sources of variability in LBM measured by BIA, as well as supervised central training in electrode placement and use of published validated equations for calculating LBM and fat. We also acknowledge that, because this study was nearly completed by the time HIV-associated lipodystrophy was first reported in the literature, we cannot exclude the possibility that our calculated values for LBM may have been affected by alterations in body morphology in our subjects.
In men with HIV-associated wasting syndrome, LBM is pos- itively correlated with functional status, as assessed by the 6-min walk test and the determination of upper and lower extremity isometric strength [29] . Because improvement in functional performance is an important expected result of antiretroviral therapy or treatment modalities for HIV wasting, there is a need for the development of an easily administered and reliable surrogate instrument to assess functional performance in clinical studies. A positive association between improvement in LBM and improvement in functional performance (as assessed by HAP) was found in this study for subjects who were antiretroviral naive at baseline. These results suggest that validation of this instrument in the HIV-infected population may be warranted to assess its potential usefulness as a tool for assessing changes in functional performance in future clinical studies. In summary, in this large group of subjects, initiation of HAART was associated with only modest increases in weight and LBM. An association was observed after treatment between weight gain and HIV virological response at 16 weeks and between increased LBM and HIV virological response at 48 weeks. Substantially smaller increases in weight and LBM were found in antiretroviral-experienced subjects, compared with those who were antiretroviral naive. The use of adefovir in many subjects in the antiretroviral-experienced cohort was associated with smaller increases in weight and LBM and may, in part, explain the poor response found in this cohort. Greater degrees of immunologic and virological compromise at baseline were found to be associated with greater short-term increases in weight and LBM. Improved functional performance as assessed by HAP was associated with increases in LBM at 48 weeks after the initiation of HAART in antiretroviral-naive subjects.
In conclusion, future studies of body composition in HIV should consider the potential existence of other factors that affect weight and LBM increase other than simple virological control, as assessed by plasma HIV-1 RNA levels. In particular, those factors that may differ between antiretroviral-naive and antiretroviral-experienced subjects should be considered. Because medications can clearly induce changes in weight, body composition analyses should be incorporated as part of future clinical trials of new antiretroviral medications. Finally, the observed association between increases in LBM and improvement in functional performance underscores the need for continued investigation of means to promote or maintain optimal body composition in persons infected with HIV.
